|
|
|
Home >
Anti-aging Research >
Proscar/Avodart
Avodart (dutasteride)
Related Topics:
Where to purchase:
Alternative News:
- See saw palmetto
- Relieve Common Men’s
Condition with Saw Palmetto Extract - Healthwell Exchange Daily News,
9/16/04 -
"Comparison trials found its effects to be similar
to those of finasteride and tamsulosin ... however, while some men using the
standard medications experienced sexual dysfunction as a side effect, men
using the herbal extract did not" - See
iHerb or
Vitacost
saw palmetto products.
News & Research:
-
Avodart (dutasteride) - rxlist.com - "AVODART
(dutasteride) is a synthetic 4-azasteroid compound that is a selective
inhibitor of both the type 1 and type 2 isoforms of steroid 5a-reductase
(5AR), an intracellular enzyme that converts testosterone to
5a-dihydrotestosterone (DHT)"
-
How Best to Fight Hair Loss in Men - WebMD, 2/10/22 -
"The top-ranking treatment was dutasteride (Avodart)
capsules, at a dose of 0.5 milligrams a day. On average, it produced the biggest
increase in total hair count after six months of use. That means men who use it
can expect more hair to crop up where there was none, though that includes
smaller, "peach fuzz" hairs"
-
Hair Loss Drug Propecia Carries Risk of Losing Something Else - NBC News,
3/10/17 - "It's a low risk— overall, just 1.4 percent of
men who took the drugs suffered long-term erectile dysfunction. But it lasted a
very long time: more than 3 ½ years after they stopped taking the drugs ... The
younger the men, the bigger the risk ... The drugs are sold under the brand
names Propecia, Proscar and Avodart and are known generically as finasteride and
dutasteride ... It was a hard problem to fix. Taking Viagra or other drugs did
not seem to help ... "I have hundreds of these patients," he told NBC News.
"They have low libido. They have flat emotions. They see a woman, they say
intellectually, 'I know I am supposed to be interested in you. But I am actually
not interested in you'. They have muted orgasms, reduced volume of ejaculate,
reduced penile sensation.""
-
Risk of Erectile
Dysfunction Associated With Use of 5-α Reductase Inhibitors for Benign Prostatic
Hyperplasia or Alopecia - Medscape, 10/20/16 - "5-α
reductase inhibitor (finasteride or dutasteride) ... 5-α reductase inhibitors do
not seem to significantly increase the risk of incident erectile dysfunction,
regardless of indication for use. Risk of erectile dysfunction increased with
longer duration of benign prostatic hyperplasia"
-
In Prostate Hyperplasia,
Combo Pill Slows Progress - Medscape, 4/18/14 - "All
men received lifestyle advice about caffeine and alcohol avoidance, fluid
management, and bladder retraining. They were then randomized to watchful
waiting (n = 373) or to daily treatment for 2 years with a single capsule
containing the 5-alpha reductase inhibitor dutasteride 0.5 mg plus the alpha
blocker tamsulosin 0.4 mg (n = 369) ... At the end of the study, the rate of
clinical progression of benign prostate hyperplasia was 43.1% lower in the
treatment group than in the watchful waiting group (18% vs 29%; P < .001) ...
Similarly, improvements in hyperplasia symptoms and related quality of life were
significantly greater the treatment group"
-
Follow-Up to REDUCE Study Shows Low Rate of Prostate Cancer Diagnosis -
Science Daily, 1/22/13 - "The four-year REDUCE
(REduction by DUtasteride of prostate Cancer Events) clinical study evaluated
prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase
inhibitor (5ARI) typically used to treat enlarged prostate ... dutasteride
decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared
to a placebo group ... few new prostate cancers were detected during the
two-year follow-up in either treatment group and no deaths were reported.
However, the former dutasteride group produced double the number of cancers than
the former placebo group (14 vs. 7). Investigators hypothesize that any prostate
cancer that may have been suppressed by dutasteride during REDUCE was no longer
being suppressed for those subjects who did not continue on 5ARI therapy ...
Overall, men in either group who took a 5ARI during the follow-up study tended
to have fewer cancers"
-
Muscle Gain From
Testosterone Not Hampered by Dutasteride - Medscape, 3/6/12 -
"Sexual function was not significantly related to
testosterone dose or testosterone concentrations during treatment, and did not
differ significantly between placebo and dutasteride groups ... [T]he inhibition
of testosterone's conversion to DHT by dutasteride had no significant effect on
the ability of testosterone to exert its effects on muscle mass and strength,
sexual function, erythropoiesis, plasma lipid levels, prostate volume, and sebum
production"
-
Dutasteride Is Seen to Curtail Cancer Left in Prostate - NYTimes.com,
1/23/12 - "Two previous studies suggested that
dutasteride and a similar drug, finasteride, could actually protect men from
prostate cancer ... Three years later, the cancer had progressed in 54 men in
the dutasteride group, or 38 percent, and in 70 men in the placebo group, or 48
percent"
-
The Impact of Current BPH Treatment on Sexual Function - Medscape, 10/13/11
- See table one. Some of those medications were less than the placebo. For
example, Alfuzosin had a 3% ED rate but the placebo was 4%. The article didn't
cover
gynecomastia which can be a problem with BPH treatments. Some studies
support letrozole to prevent
gynecomastia. I take a quarter tablet
every other day.
-
Popular
drugs for common male health problems can affect their sexual health -
Science Daily, 3/7/11
-
Drugs
for hair loss and benign prostatic hyperplasia may result in loss of libido,
erectile dysfunction in men - Science Daily, 1/11/11 -
"5a-reductase inhibitors (5a-RIs), while improving
urinary symptoms in patients with benign prostatic hyperplasia (BPH) and
possible hair loss prevention, produces significant adverse effects in some
individuals including loss of libido, erectile dysfunction (ED), ejaculatory
dysfunction and potential depression" - Note: That goes back and forth.
One study claimed that finasteride improved sex after after six months of taking
it. Regarding gynaecomastia, if you're taking low dose letrozole to increase
testosterone and to prevent aromatization it many also help prevent
gynaecomastia.
-
Prostate Drug May Not Dim Sex - WebMD, 6/26/07 -
"Six months after the men started taking their assigned drugs, the survey
scores were about three points higher for the men taking Proscar. By the end
of the study, that gap narrowed to about two points"
-
Prostate Drug Doesn't Limit Sexual Function In Most Men - Science Daily,
7/19/07 - "The study suggests that finasteride will
cause little or no sexual dysfunction for most men who decide to take it"
-
Ask a Medical Question - Can letrozole cure gynecomastia - JustAnswer -
"Letrozole may be effective in preventing and
reversing the gynaecomastia provided it is used early enough in steroid
induced gynaecomastia" - See letrozole at
OffshoreRx1.com. I
believe the recommended dose is something like a quarter tablet every three
days but don't quote me on it. That's what I take.
-
PSA test
better predicts cancer in men taking prostate-shrinking drug - Science
Daily, 12/16/10 - "Dutasteride lowers PSA levels by
about half within six months. But the researchers found that even a slight rise
in PSA levels among men taking the drug was a stronger indicator of prostate
cancer, particularly aggressive tumors that require early diagnosis and
treatment, than rising PSA levels in men who took a placebo ... dutasteride
reduced the risk of a prostate cancer diagnosis by 23 percent. Dutasteride
appears to keep tumors small or shrink them to the point that they are less
likely to be detected by a biopsy ... Over four years, PSA levels increased in
72 percent of men taking a placebo and only 29 percent of men taking
dutasteride, the data show"
-
FDA
Approves Dutasteride/Tamsulosin Combo Pill for BPH - Medscape, 6/18/10 -
"daily use of the drug combination yielded significantly
greater relief of BPH symptoms compared with either 0.5 mg dutasteride or 0.4 mg
tamsulosin alone, as measured by point changes on the International Prostate
Symptom scale from baseline (mean Δ, −6.2 vs −4.9 and −4.3; P < .001 for both).
The difference was observed by month 9 and continued through month 24"
-
The Effect
of Short-term Dutasteride Intake in Early-stage Prostate Cancer: Analysis of 148
Patients Who Underwent Three-dimensional Prostate Mapping Biopsy - Urology.
2010 May 14 - "transperineal three-dimensional mapping
(TP-3DM) biopsy ... We observed a 24.3% decrease in the proportion of upstaging
and/or upgrading of prostate cancer in men who received dutasteride at least 3
months before 3D prostate TP-3DM biopsy. Thus, the effect of dutasteride on
prostate cancer may have implications for its potential use as a secondary
chemoprevention agent" - See dutasteride at
OffshoreRx1.com.
-
Avodart May Lower Prostate Cancer Risk - WebMD, 3/31/10 -
"those who took the drug Avodart had a 23% lower risk of
being diagnosed with prostate cancer over four years of treatment, compared to
men who did not take the drug" - See Avodart (dutasteride) at
OffshoreRx1.com.
-
Combination therapy more effective for enlarged prostate - Science Daily,
3/2/10 - "On the strengths of both dutasteride and
tamsulosin, participants reported fewer symptoms, and we observed a 25 percent
reduction in prostate volume ... subjects who received the combination therapy
also showed a 50 percent reduction of prostate-specific antigen (PSA), a protein
produced by both cancerous and noncancerous prostate tissue ... Compared with
tamsulosin alone, the combination of drugs reduced the incidence of acute
urinary retention by 67 percent and reduced the need for BPH-related surgery by
70 percent"
-
Dutasteride Reduces Risk for Biopsy-Detectable Prostate Cancer in Men at
Increased Risk - Doctor's Guide, 12/1/09 - "Compared
with placebo, active treatment also showed significantly lower risks for
(respectively) HG-PIN (5.4% vs 3.5%; RRR, 34%; P = .0053), ASAP (5.1% vs 3.6%;
RRR, 28%; P = .0274), AUR (7.1% vs 1.4%; RRR, 80.4%; P < .0001), BPH-related
surgery (5.7% vs 1.4%; RRR 75.6%; P < .0001), and UTI (9.6% vs 5.8%; RRR, 40.8%;
P < .0001) ... Similarly, there were significant reductions for mean prostate
volume (18.7% increase vs 16.9% decrease; P < .0001) and IPSS (+1.14 vs -0.6; P
< .0001), and slightly fewer high-grade tumours (Gleason score, 7-10) in the
dutasteride group (7.5% vs 7.0%) ... These benefits were accompanied by
significantly more frequent dutasteride-related adverse events (12% vs 19%; P <
.0001), with dutasteride treatment showing increased frequencies of decreased
libido (2.8% vs 5.5%), impotence (7.7% vs 10.9%), ejaculation disorders (0.5% vs
2.4%), and breast disorders (1.9% vs 3.5%)"
-
Diet, Drugs May Stop Prostate Cancer - WebMD, 9/24/07
-
Diet And
Medications May Assist Prevention Of Prostate Cancer - Science Daily,
9/24/07 - "dutasteride, has reduced by 50 percent the
number of cancerous biopsies among men with benign prostatic hypertrophy ... In
one study of selenium, the incidence of prostate cancer was reduced by 49
percent over ten years ... Data already suggests novel uses of statins, commonly
prescribed cholesterol-lowering agents, and insulin modulating drugs, such as
metformin or the glitazones"
-
Treatment Found To Reverse Hair Loss - Science Daily, 6/11/07 -
"one of each pair of twins was given 0.5 mg/day of
the medication, the other receiving a placebo ... After both 6 and 12-month
intervals, hair loss was found to not only have been halted in twins using
dutasteride, but hair growth was actively improved"
Abstracts:
-
Effects of
dutasteride on serum free-testosterone and clinical significance of testosterone
changes - Andrologia. 2016 Mar 8 - "Serum
free-testosterone levels were 20.4% higher after 1 month and remained constant
thereafter ... These results indicate that dutasteride increases serum
free-testosterone levels in BPH patients, particularly with low baseline
free-testosterone levels, and the increase in free-testosterone may have further
add-on impacts on their urinary tract symptoms"
-
Dutasteride
in men receiving testosterone therapy: a randomised, double-blind study -
Andrologia. 2014 Feb 6 - "We investigate the impact of
dutasteride on prostate specific antigen (PSA) and prostate volume in men
receiving testosterone (T) therapy ... Serum levels of PSA, T and
dihydrotestosterone (DHT) and responses to the International Index of Erectile
Function (IIEF) and Male Sexual Health Questionnaire (MSHQ) questionnaires were
determined at baseline and at 3, 6, 9 and 12 months ... Men receiving
dutasteride had a significant decrease in PSA (-0.46 ± 0.81 ng ml-1 ; P = 0.04)
and in PV (-6.65 ± 11.0%; P = 0.03) from baseline over 12 months. DHT decreased
significantly for men on dutasteride compared with men receiving placebo (P =
0.02). When compared with men who received placebo, men who received dutasteride
demonstrated nonsignificant trends towards decreased PSA (-0.46 versus 0.21 ng
ml-1 ; P = 0.11), PV (-6.65% versus 3.4%; P = 0.08) and MSHQ scores (-10.2
versus 5.6; P = 0.06). Dutasteride reduces PSA and PV for men on T therapy, but
perhaps less so than in men without T therapy"
-
Systematic
review evaluating cardiovascular events of the 5-alpha reductase inhibitor -
Dutasteride - J Clin Pharm Ther. 2013 Jul 1 - "We
did not find consistent evidence of a significant association between
dutasteride therapy and the risk of cardiovascular adverse events"
-
A 5-year
retrospective analysis of 5α-reductase inhibitors in men with benign prostatic
hyperplasia: finasteride has comparable urinary symptom efficacy and prostate
volume reduction, but less sexual side effects and breast complications than
dutasteride - Int J Clin Pract. 2012 Nov;66(11):1052-5. doi -
"The incidence of erectile dysfunction, ejaculatory
dysfunction and decreased libido resulting in discontinuation from therapy was
significantly (p<0.01) higher in the dutasteride (5.1%, 2.4%, 2.7% respectively)
compared with the finasteride (2.1%, 1.8%, 1.4% respectively) group. In
addition, the incidence of self-reported breast tenderness and/or enlargement
was significantly (p<0.01) greater in the dutasteride (3.5%) compared with the
finasteride (1.2%) group. Conclusions: In this retrospective analysis of data
from consecutive patients treated at a single clinic, both finasteride and
dutasteride were effective therapies for the management of lower urinary tract
symptoms. However, dutasteride resulted in significantly more sexual side
effects and breast complications than finasteride" - Note: I'm not sure
that makes sense. The first sentence says "resulting in discontinuation from
therapy"
-
Dutasteride/Tamsulosin: in benign prostatic hyperplasia - Drugs Aging. 2012
May 1;29(5):405-19 -
"Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day
improved lower urinary tract symptoms (LUTS) to a significantly greater extent
than dutasteride or tamsulosin alone in men with BPH, moderate to severe LUTS
and an increased risk of disease progression, according to the results of the
randomized, double-blind, multinational CombAT trial. The mean change from
baseline in the total International Prostate Symptom Score was significantly
greater with dutasteride plus tamsulosin than with dutasteride or tamsulosin
alone after 2 years (primary endpoint) and 4 years of therapy. After 4 years'
therapy in the CombAT trial, the time to first acute urinary retention or
BPH-related surgery (primary endpoint) significantly favoured men with
symptomatic BPH who were receiving dutasteride plus tamsulosin versus those
receiving tamsulosin alone, with no significant difference between recipients of
dutasteride plus tamsulosin and recipients of dutasteride alone. In the CombAT
trial, health-related quality of life and treatment satisfaction were improved
to a significantly greater extent with dutasteride plus tamsulosin than with
dutasteride or tamsulosin alone. Combination therapy with oral dutasteride plus
tamsulosin was generally well tolerated in patients with symptomatic BPH in the
CombAT trial"
-
Dutasteride
Improves Outcomes of Benign Prostatic Hyperplasia When Evaluated for Prostate
Cancer Risk Reduction: Secondary Analysis of the REduction by Dutasteride of
Prostate Cancer Events (REDUCE) Trial - Urology. 2011 Jul 14 -
"During the 4-year study, the International Prostate
Symptom Score increased in placebo-treated patients, while dutasteride-treated
patients had a stabilized or decreased International Prostate Symptom Score and
improved BPH Impact Index and quality of life due to urinary symptom scores
across all prostate volume quintiles (including prostate glands smaller than
those studied in previous dutasteride trials). 48 months, the incidence of acute
urinary retention or BPH-related surgery was significantly less in the
dutasteride group (2.5%) than in the placebo group (9%) overall (P < .001) and
in each baseline prostate volume quintile (P < .01)"
-
Effect of
dutasteride, tamsulosin and the combination on patient-reported quality of life
and treatment satisfaction in men with moderate-to-severe benign prostatic
hyperplasia: 4-year data from the CombAT study - Int J Clin Pract. 2010 May
7 - "Subjects were randomised to receive 0.5 mg
dutasteride, 0.4 mg tamsulosin or the combination once daily for 4 years ... At
4 years, combination therapy resulted in significantly superior improvements
from baseline in BII and IPSS Q8 than either monotherapy; these benefits were
observed from 3 months onwards compared with dutasteride and from 9 months (BII)
or 12 months (IPSS Q8) onwards compared with tamsulosin. Also at 4 years, the
PPSM questionnaire showed that a significantly higher proportion of patients was
satisfied with, and would request treatment with, combination therapy compared
with either monotherapy. Conclusions: Combination therapy (dutasteride plus
tamsulosin) provides significantly superior improvements in patient-reported
quality of life and treatment satisfaction than either monotherapy at 4 years in
men with moderate-to-severe BPH symptoms" - See dutasteride at
OffshoreRx1.com.
-
Association of Sexual Dysfunction With Lower Urinary Tract Symptoms of BPH
and BPH Medical Therapies: Results From the BPH Registry - Urology. 2009
Jan 21 - "The severity of lower urinary tract
symptoms (LUTS) has correlated with erectile dysfunction (ED) and
ejaculatory dysfunction (EjD) ... The alpha(1A)-subtype nonsuperselective
quinazoline alpha(1)-blockers alfuzosin, doxazosin, and terazosin appeared
to be associated with better ejaculatory function than were the
alpha(1A)-subtype superselective sulfonamide alpha(1)-blocker tamsulosin,
5alpha-reductase inhibitors, and alpha(1)-blocker plus 5alpha-reductase
inhibitor combination therapy"
-
Effect of Dutasteride
on Intraprostatic Androgen Levels in Men With Benign Prostatic Hyperplasia
or Prostate Cancer - Urology. 2008 Aug 19 - "The
results of our study have shown that dutasteride provides near-maximal
suppression of both serum and intraprostatic DHT levels in men with benign
prostatic hyperplasia or prostate cancer at all points assessed"
-
The Rationale for
Inhibiting 5alpha-Reductase Isoenzymes in the Prevention and Treatment of
Prostate Cancer - J Urol. 2008 Feb 14 - "The 2
5alpha-reductase inhibitors currently clinically available are finasteride,
a type 2 5alpha-reductase inhibitor, and dutasteride, a dual
5alpha-reductase inhibitor. Dual inhibition by dutasteride has been shown to
translate into a greater degree and consistency of dihydrotestosterone
suppression compared with finasteride. The Prostate Cancer Prevention Trial
showed that finasteride significantly decreased the 7-year risk of prostate
cancer in men with prostate specific antigen 3.0 ng/ml or less, while the
ongoing Reduction by Dutasteride of Prostate Cancer Events study is
assessing whether dutasteride decreases the risk of biopsy detectable
prostate cancer in men with prostate specific antigen 2.5 to 10 ng/ml and a
previous negative biopsy"
-
The importance of dual 5alpha-reductase inhibition in the treatment of male
pattern hair loss: results of a randomized placebo-controlled study of
dutasteride versus finasteride - J Am Acad Dermatol. 2006
Dec;55(6):1014-23 - "Dutasteride increased target
area hair count versus placebo in a dose-dependent fashion and dutasteride
2.5 mg was superior to finasteride at 12 and 24 weeks"
- Note: Dutasteride is Avodart®. See dutasteride at
OffshoreRx1.com
or
International Antiaging Systems.
Related Searches:
70520
|
|
